Radius Health has announced the completion of enrollment of patients for the Phase II clinical trial of BA058, the company’s bone anatomic candidate for osteoporosis. The trial will study the capability of BA058 to build new bones in postmenopausal women. The clinical trial will study 244 postmenopausal women with osteoporosis who are otherwise healthy.

Roche’s Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients’ physical function after one year of therapy, leading to a better quality of life. Results from the LITHE1 trial showed that a greater proportion of patients treated with Actemra in combination with a commonly used RA drug called methotrexate (MTX) benefited from a significant inhibition of structural damage during 12 months of therapy, compared to patients treated with MTX alone. Additionally, Actemra improved the patients’ ability to perform normal daily activities.